Nintedanib (Prutis): Antifibrotic Therapy for Pulmonary Fibrosis & ILDs

Prutis, containing Nintedanib, is an antifibrotic medicine widely prescribed for Idiopathic Pulmonary Fibrosis (IPF), Interstitial Lung Disease (ILD), and Systemic Sclerosis-associated ILD (SSc-ILD). These conditions are characterized by progressive lung fibrosis, leading to breathing difficulties, reduced oxygen levels, and decreased quality of life.

Uses and Benefits
Nintedanib works by slowing the progression of lung fibrosis, helping patients maintain lung function for longer. It is available in 150 mg and 100 mg soft gelatin capsules, making it convenient for daily administration. This medicine is particularly effective in IPF, a chronic and often rapidly progressing condition, and is also used in SSc-ILD to manage fibrosis associated with autoimmune disorders.

Mechanism of Action
Nintedanib functions as a tyrosine kinase inhibitor, targeting growth factors like PDGF, VEGF, and FGF that play a role in the fibrotic process. By inhibiting these pathways, Nintedanib reduces the scarring of lung tissue, slowing the decline in lung function.

Side Effects
While generally well-tolerated, Nintedanib may cause diarrhea, nausea, vomiting, abdominal pain, liver enzyme elevation, and occasionally weight loss. Regular monitoring of liver function tests is recommended during treatment. Most side effects are manageable with dose adjustments or supportive care.

Conclusion
Prutis (Nintedanib) offers a promising solution for patients with IPF, ILD, and SSc-ILD, helping to slow disease progression and improve quality of life. Early diagnosis and timely treatment are crucial for optimal results. Patients should consult their healthcare provider to determine the appropriate dosage and monitor side effects closely.